Microbial-Derived Antioxidants in Intestinal Inflammation: A Systematic Review of Their Therapeutic Potential
Metadatos
Afficher la notice complèteAuteur
García Mansilla, María José; Rodríguez Sojo, María Jesús; Roxana Lista, Andrea; Ayala Mosqueda, Ciskey Vanessa; Ruiz Malagón, Antonio Jesús; Ho Plagaro, Ailec; Gálvez Peralta, Julio Juan; Rodríguez Nogales, Alba; Rodríguez Sánchez, María JoséEditorial
MDPI
Materia
Dysbiosis Gut Inflammation Microbial-derived antioxidants Microbiome
Date
2025-03-06Referencia bibliográfica
García Mansilla, M.J.; Rodríguez Sojo, M.J.; Lista, A.R.; Ayala Mosqueda, C.V.; Ruiz Malagón, A.J.; Ho Plagaro, A.; Gálvez, J.; Rodríguez Nogales, A.; Rodríguez Sánchez, M.J. Microbial-Derived Antioxidants in Intestinal Inflammation: A Systematic Review of Their Therapeutic Potential. Antioxidants 2025, 14, 321. https://doi.org/10.3390/antiox14030321
Patrocinador
Junta de Andalucía (CTS 164); Instituto de Salud Carlos III (Spain); Ministerio de Ciencia e Innovación (Spain); Fondo Europeo de Desarrollo Regional (FEDER); European Union PI18/00826, PY20-01157, PI20/01447, B-CTS-664-UGR20, PI19/01058, PI24/02089, JDC2022-049478-I, CD23/00117, IFI21/00030Résumé
The potential of microbial-derived antioxidants to modulate intestinal inflammation is increasingly recognized, which is especially important in inflammatory bowel diseases (IBD). Oxidative stress, a major contributor to chronic intestinal inflammation, is the result of an imbalance between the production of reactive oxygen species (ROS) and the body’s antioxidant defenses. This systematic review explores the role of microbial-derived antioxidants in alleviating IBD. Among the main findings are certain compounds, such as exopolysaccharides (EPS) and short-chain fatty acids (SCFAs), which have demonstrated their ability to neutralize ROS and strengthen the integrity of the intestinal barrier, thereby attenuating inflammatory responses. These antioxidants offer the dual benefit of mitigating oxidative stress and rebalancing the gut microbiota, which is often disrupted in IBD. Evidence from preclinical and clinical studies provides a better understanding of the mechanisms involved in the effects of these microbial antioxidants. Conventional treatments for IBD primarily focus on immune modulation. In this context, the integration of microbial-derived antioxidants could offer a complementary approach by addressing both oxidative damage and gut dysbiosis. Further research and clinical trials are essential to establish standardized treatment guidelines and clarify the long-term efficacy of these promising therapeutic agents.